Strep pneumoniae infection - Symptoms, Causes, Treatment & Prevention

Overview

Streptococcus pneumoniae (often called “pneumococcus”) is a gram‑positive bacterium that commonly colonises the upper respiratory tract. When it invades sterile sites such as the lungs, bloodstream, or meninges, it causes a Strep pneumoniae infection. The most frequent clinical manifestations are community‑acquired pneumonia, sinusitis, otitis media, and meningitis.

• Who it affects: All ages can be infected, but the highest burden falls on children <5 years, adults > 65 years, and individuals with chronic medical conditions.
• Prevalence: In the United States, pneumococcus accounts for ~4 million cases of disease and 900 000 hospitalisations annually; worldwide it is responsible for an estimated $15 billion in health‑care costs each year (CDC, 2023; WHO, 2022).

Symptoms

The symptoms vary depending on the site of infection. Below is a complete list with brief descriptions.

Respiratory (Pneumonia)

• Fever & chills – often > 38 °C (100.4 °F), may be high‑grade.
• Cough – productive, sputum may be rusty‑brown.
• Shortness of breath – especially on exertion.
• Chest pain – pleuritic (sharp, worsens with breathing).
• Fatigue & malaise.

Ear, Nose & Throat

• Otitis media: ear pain, fever, irritability (children).
• Sinusitis: facial pressure, purulent nasal discharge, headache.

Invasive Disease

• Meningitis: severe headache, neck stiffness, photophobia, altered mental status, seizures.
• Bacteremia (sepsis): fever, chills, rapid heart rate, low blood pressure, confusion.
• Peritonitis (in patients on peritoneal dialysis): abdominal pain, cloudy dialysate.

Systemic

• Muscle aches (myalgia).
• Loss of appetite.
• Weight loss (in chronic or recurrent infections).

Causes and Risk Factors

What causes infection?

Pneumococcus is transmitted via respiratory droplets from a colonised person. Colonisation is usually harmless; disease occurs when the bacteria cross the mucosal barrier—often after a viral upper‑respiratory infection that damages epithelial cells.

Key risk factors

• Age: <5 years and > 65 years.
• Chronic lung disease: COPD, asthma, bronchiectasis.
• Heart disease, diabetes, liver or kidney disease.
• Immunocompromise: HIV/AIDS, solid‑organ transplant, chemotherapy, splenectomy.
• Smoking & alcohol abuse.
• Living in crowded settings: prisons, nursing homes, daycare centers.
• Absence of vaccination: lack of pneumococcal conjugate (PCV13) or polysaccharide (PPSV23) immunisation.

Diagnosis

Prompt diagnosis relies on a combination of clinical judgment and laboratory testing.

1. Physical examination

• Crackles or bronchial breath sounds on auscultation.
• Signs of meningitis (neck rigidity, Kernig’s sign).

2. Laboratory tests

• Complete blood count (CBC): leukocytosis with neutrophil predominance.
• Blood cultures: gold standard for bacteremia; positivity in 10‑30 % of pneumococcal pneumonia.
• Sputum Gram stain & culture: Gram‑positive, lancet‑shaped diplococci; culture confirms susceptibility.
• Urinary antigen test: rapid (15‑30 min) detection of pneumococcal polysaccharide; useful even after antibiotics started.
• Polymerase chain reaction (PCR): increasingly used for CSF, blood, or respiratory samples for rapid identification.

3. Imaging

• Chest X‑ray: lobar consolidation typical of pneumococcal pneumonia; may show cavitation in severe cases.
• CT scan: reserved for complicated cases or when X‑ray is equivocal.
• CT/MRI of brain: when meningitis or brain abscess is suspected.

4. Lumbar puncture

Indicated for suspected meningitis. CSF findings include elevated white cells (neutrophilic), low glucose, high protein, and positive Gram stain or PCR for S. pneumoniae.

Treatment Options

Treatment should be started promptly, often before culture results return, based on local resistance patterns.

Antibiotic therapy

Clinical scenario	First‑line agents (per IDSA guidelines, 2023)	Notes
Uncomplicated community‑acquired pneumonia (CAP) – no risk factors for resistant strains	High‑dose amoxicillin 1 g PO q6h OR oral cefuroxime 250 mg PO q12h	Duration 5‑7 days.
CAP with penicillin‑resistant S. pneumoniae risk (recent antibiotics, comorbidities)	Levofloxacin 750 mg PO daily OR moxifloxacin 400 mg PO daily	Fluoroquinolones reserved for allergy or resistance.
Severe pneumonia, meningitis, or bacteremia	IV ceftriaxone 2 g q24h ± vancomycin (if high‑level resistance suspected)	Switch to oral step‑down when clinically stable.
Allergy to β‑lactams	Clindamycin 600 mg IV q8h OR doxycycline 100 mg PO bid	Check local resistance rates.

Adjunctive care

• Supplemental oxygen for hypoxia (SpO₂ < 92 %).
• Intravenous fluids if septic.
• Analgesics/antipyretics (acetaminophen or ibuprofen).
• Chest physiotherapy for patients with retained secretions.

Lifestyle & supportive measures

• Stop smoking; avoid exposure to second‑hand smoke.
• Stay hydrated; adequate nutrition to support immune function.
• Vaccination updates (see Prevention section).

Living with Strep pneumoniae infection

Even after the acute phase, patients may need to manage lingering symptoms and reduce recurrence risk.

Daily management tips

• Medication adherence: complete the full antibiotic course even if you feel better.
• Symptom monitoring: track fever, cough, breathing difficulty, and energy levels.
• Rest & pacing: avoid strenuous activity for at least 7‑10 days; gradually increase activity as tolerated.
• Hydration & nutrition: aim for at least 2 L of fluid per day; include protein‑rich foods to aid tissue repair.
• Pulmonary hygiene: perform deep‑breathing exercises, use an incentive spirometer if prescribed.
• Follow‑up appointments: usually 1‑2 weeks after discharge to ensure radiographic resolution and check labs.
• Vaccination reminders: keep a record of PCV13 and PPSV23 dates.

When to contact your clinician

• Fever persists > 48 h after starting antibiotics.
• Worsening cough or new sputum colour.
• Increasing shortness of breath or chest pain.
• New neurological symptoms (headache, confusion).

Prevention

Prevention is the most effective strategy, especially for high‑risk groups.

• Vaccination:
  • Pneumococcal conjugate vaccine (PCV13) – recommended for all children <2 years, adults ≥ 65 years, and high‑risk adults.
  • Pneumococcal polysaccharide vaccine (PPSV23) – given at age ≥ 65 years and to adults 19‑64 with chronic conditions.
• Hand hygiene: wash hands with soap for at least 20 seconds; use alcohol‑based sanitizer when soap unavailable.
• Respiratory etiquette: cover coughs/sneezes with tissue or elbow.
• Avoid smoking and limit alcohol: both impair mucociliary clearance.
• Manage chronic diseases: optimise diabetes, asthma, COPD control.
• Stay up‑to‑date with influenza vaccination: viral infections predispose to secondary pneumococcal disease.

Complications

If not treated promptly or adequately, S. pneumoniae can cause serious sequelae.

• Empyema: collection of pus in the pleural space; may require chest tube drainage.
• Septic shock: profound hypotension with multi‑organ failure.
• Meningitis: can lead to hearing loss, cognitive deficits, or hydrocephalus.
• Endocarditis: especially in persons with pre‑existing heart valve disease.
• Osteomyelitis & septic arthritis: spread via bloodstream.
• Chronic lung disease exacerbation: especially in COPD patients.

When to Seek Emergency Care

---

Sources: CDC. “Pneumococcal Disease.” 2023; WHO. “Pneumococcal Disease.” 2022; Mayo Clinic. “Pneumonia.” 2024; IDSA Guidelines for Community‑Acquired Pneumonia, 2023; NIH. “Vaccines for Pneumococcal Disease.” 2024; Cleveland Clinic. “Streptococcus pneumoniae Infections.” 2024.